Innovating Works

InDx

Financiado
InDx an innovative implant that restores natural motion to patients with thumb...
InDx an innovative implant that restores natural motion to patients with thumb base joint arthritis The thumb base joint is fundamental for human dexterity and functional activity but is prone to debilitating arthritis. Approximately 5% of the world population suffers from this condition with over 25 million Europeans affected.... The thumb base joint is fundamental for human dexterity and functional activity but is prone to debilitating arthritis. Approximately 5% of the world population suffers from this condition with over 25 million Europeans affected. Simple tasks become impossible such as getting dressed, opening a jar, using a key to open a door. This is certainly a relevant socioeconomic and humanitarian concern, which causes a substantial cost burden on healthcare systems, yet the effective treatment for end-stage thumb base arthritis lags far behind other joints, given challenges of the small, complex anatomy. The InDx project aims to enable the commercialization of the InDx implant, the world’s first implant designed to accommodate the complex biomechanics of the thumb base joint and restore the natural movement of the thumb. The consortium is led by Loci Orthopaedics, a technology-driven SME spin-out company from the National University of Ireland, Galway. The partners include EndoLab in Germany, that has developed a novel dynamic test station for implants, NAMSA in the UK, a leading medical research organization with extensive experience in running international clinical investigations, and Medvie, an Irish based SME with extensive project management, dissemination and commercialization expertise. Together, the consortium have brought the implant to TRL 6 level. As part of the InDx project, the consortium will undertake the final stages of product development and will validate clinical results in a clinical study that will prepare the CE marking and market access. Market launch is planned within 24 months from the project start date, following FDA 510K approval in the USA and CE marking in Europe. The consortium estimates cumulative revenues of €51M within 5 years from the start of commercialisation and an employment growth of 25 FTEs for the consortium partners. The InDx has the potential to be a disruptive innovation in the surgical management of thumb base joint arthritis. ver más
31/12/2021
LOCI ORTHOPAEDICS...
4M€
Duración del proyecto: 30 meses Fecha Inicio: 2019-06-24
Fecha Fin: 2021-12-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2021-12-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-FTI-2018-2020: Fast Track to Innovation (FTI)
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 4M€
Líder del proyecto
LOCI ORTHOPAEDICS LIMITED No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5